{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T02:03:58Z","timestamp":1762481038607,"version":"build-2065373602"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.gore.2023.101180","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T21:25:51Z","timestamp":1680816351000},"page":"101180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The impact of adjuvant antihormonal therapy versus observation on recurrence of borderline ovarian tumors: A retrospective cohort study"],"prefix":"10.1016","volume":"47","author":[{"given":"Kelsey C.","family":"Goon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanelle","family":"Sheeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam D.","family":"Post","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Alldredge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.gore.2023.101180_b0005","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ygyno.2005.05.033","article-title":"Recurrence and prognostic factors in borderline ovarian tumors","volume":"98","author":"Ayhan","year":"2005","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.gore.2023.101180_b0010","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ygyno.2020.08.015","article-title":"Aromatase inhibitor use, side effects and discontinuation rates in gynecologic oncology patients","volume":"159","author":"Bell","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gore.2023.101180_b0015","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ejogrb.2020.11.045","article-title":"Borderline ovarian tumors: Guidelines from the French national college of obstetricians and gynecologists (CNGOF)","volume":"256","author":"Bourdel","year":"2021","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"issue":"4","key":"10.1016\/j.gore.2023.101180_b0020","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/1471-0528.13875","article-title":"Borderline ovarian tumours: a continuing conundrum?","volume":"123","author":"Cross","year":"2016","journal-title":"Br. J. Obstet. Gynaecol."},{"issue":"Suppl 1","key":"10.1016\/j.gore.2023.101180_b0025","doi-asserted-by":"crossref","first-page":"i20","DOI":"10.1093\/annonc\/mdw090","article-title":"Management of borderline ovarian tumors","volume":"27","author":"du Bois","year":"2016","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.gore.2023.101180_b0030","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2016.71.0632","article-title":"Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum","volume":"35","author":"Gershenson","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.gore.2023.101180_b0035","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ygyno.2016.01.022","article-title":"Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase","volume":"140","author":"Grabowski","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gore.2023.101180_b0040","article-title":"Oncologic and reproductive outcomes of borderline ovarian tumors in Indian population","volume":"36","author":"Kumari","year":"2021","journal-title":"Gynecol. Oncol. Rep."},{"issue":"2","key":"10.1016\/j.gore.2023.101180_b0045","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ejogrb.2009.04.031","article-title":"Long-term follow-up after ovarian borderline tumor: relapse and survival in a large patient cohort","volume":"145","author":"Lenhard","year":"2009","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"issue":"1","key":"10.1016\/j.gore.2023.101180_b0050","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ygyno.2019.08.030","article-title":"Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study","volume":"157","author":"Matsuo","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gore.2023.101180_b0055","unstructured":"National Comprehensive Cancer Network. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer (Version 5.2022). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ovarian.pdf. Accessed 12 October 2022."},{"issue":"2","key":"10.1016\/j.gore.2023.101180_b0060","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ygyno.2005.10.014","article-title":"Management of borderline ovarian tumors: results of an Italian multicenter study","volume":"101","author":"Romagnolo","year":"2006","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.gore.2023.101180_b0065","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/cncr.20080","article-title":"Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis","volume":"100","author":"Sherman","year":"2004","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.gore.2023.101180_b0070","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ygyno.2010.07.019","article-title":"Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors","volume":"119","author":"Shih","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.gore.2023.101180_b0075","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ygyno.2010.11.016","article-title":"Risk factors for recurrence of borderline ovarian tumors","volume":"120","author":"Shih","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.gore.2023.101180_b0080","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.ygyno.2006.05.014","article-title":"Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study","volume":"103","author":"Suh-Burgmann","year":"2006","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.gore.2023.101180_b0085","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.ejca.2015.01.004","article-title":"Conservative surgery in ovarian borderline tumours: a meta-analysis with emphasis on recurrence risk","volume":"51","author":"Vasconcelos","year":"2015","journal-title":"Eur. J. Cancer"}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578923000498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578923000498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T01:58:59Z","timestamp":1762480739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578923000498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":17,"alternative-id":["S2352578923000498"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2023.101180","relation":{},"ISSN":["2352-5789"],"issn-type":[{"type":"print","value":"2352-5789"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of adjuvant antihormonal therapy versus observation on recurrence of borderline ovarian tumors: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2023.101180","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101180"}}